BackSCHOTT Pharma AG KGaA Overview

SCHOTT Pharma AG KGaA Receivables

SCHOTT Pharma AG KGaA's receivables is $490M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$486.15M
↑ 17.99% YoYΔ $74.14M vs prior year quarter

Peer trimmed avg / median

Loading

SCHOTT Pharma AG KGaA Receivables History

Loading

SCHOTT Pharma AG KGaA vs. peers: Receivables Comparison

Loading

SCHOTT Pharma AG KGaA Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

SCHOTT Pharma AG KGaA (1SXP.F) FAQ

As of the most recent data (June 2026), 1SXP.F shows a receivables of $490M. That compares with $410M in the prior-year period — up 18.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 1SXP.F's receivables is now $490M (was $410M) — a 18.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether SCHOTT Pharma AG KGaA is outperforming or lagging.

Tracking 1SXP.F's receivables over time shows whether SCHOTT Pharma AG KGaA is scaling, shrinking, or reshaping that part of the business. The current reading is $490M That compares with $410M in the prior-year period — up 18.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has SCHOTT Pharma AG KGaA's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $490M) with ownership activity and broader fundamentals.

Questions & Answers